<DOC>
	<DOCNO>NCT00278876</DOCNO>
	<brief_summary>The presence c-kit mutation independent poor prognostic factor relapse addition large size ( &gt; 5 cm ) high mitotic rate ( &gt; 5/50 high power field [ HPF ] ) localize gastrointestinal stromal tumor ( GIST ) patient underwent complete surgical resection . In addition , localized GIST exon 11 c-kit mutation feature high-risk relapse accord National Institute Health ( NIH ) consensus guideline ( tumor size &gt; 10 cm mitotic count &gt; 10/50 HPF ) also high-risk relapse . Until recently , effective therapy advance , unresectable GISTs . However , new agent , imatinib mesylate , show promise metastatic setting , c-kit exon 11 mutation strong prognostic factor well response survival . It reasonable try imatinib earlier minimal residual status especially patient high risk relapse high probability response imatinib .</brief_summary>
	<brief_title>Adjuvant Imatinib High-risk Gastrointestinal Stromal Tumor ( GIST ) With C-kit Mutation</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Histologically proven diagnosis GIST , positive immunostaining KIT ( CD117 ) Tumor size &gt; 5 cm mitotic rate &gt; 5/50HPF ( High Power Field ) , tumor size &gt; 10 cm irrespective mitotic rate , mitotic rate &gt; 10/50 HPF irrespective tumor size . Presence mutation exon 11 ckit gene . Surgery perform 3 week 8 week administration Imatinib mesylate . No evidence residual macroscopic microscopic disease surgery . Absence distant metastases No prior radiation therapy , prior chemotherapy , prior therapy Imatinib mesylate , molecular target biological therapy . Age 18 yr old ECOG ( Eastern Cooperative Oncology Group electrocorticogram ) performance status = 02 No New York Heart Association ( NYHA ) Class 3~4 cardiac problem Absence severe and/or uncontrolled concurrent medical disease ( e.g. , uncontrolled diabetes , uncontrolled chronic renal disease , uncontrolled liver disease , include chronic viral hepatitis judge risk reactivation , uncontrolled active infection , human immunodeficiency virus ( HIV ) infection , etc. ) . No ongoing pregnancy nursing.. No prior , ongoing malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer adequately treat cancer eradicative intent patient continuously diseasefree 5 year . No use coumarin derivative time treatment start . Adequate liver function , define serum bilirubin &lt; 1.5 x institutional upper limit normal ( IULN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5 IULN , obtain within 7 day prior randomization . Adequate renal function , define serum creatinine &lt; 1.5 x IULN , obtain within 7 day prior randomization . Absolute neutrophil count ( ANC ) &gt; 1.5 x 109/l platelet count &gt; 100 x 109/l obtain within 7 day prior randomization . Baseline hemoglobin &gt; 9 g/dl ( may achieve transfusion need ) . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>GIST</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Adjuvant therapy</keyword>
	<keyword>Kit mutation</keyword>
</DOC>